thalidomide has been researched along with Mononeuropathies in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Mononeuropathies: Disease or trauma involving a single peripheral nerve in isolation, or out of proportion to evidence of diffuse peripheral nerve dysfunction. Mononeuropathy multiplex refers to a condition characterized by multiple isolated nerve injuries. Mononeuropathies may result from a wide variety of causes, including ISCHEMIA; traumatic injury; compression; CONNECTIVE TISSUE DISEASES; CUMULATIVE TRAUMA DISORDERS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an oral agent with significant activity in one-third of patients with refractory myeloma." | 6.71 | Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Poziopoulos, C; Xilouri, I; Zomas, A; Zorzou, MP, 2004) |
| "Thalidomide is an oral agent with significant activity in one-third of patients with refractory myeloma." | 2.71 | Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Poziopoulos, C; Xilouri, I; Zomas, A; Zorzou, MP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dimopoulos, MA | 1 |
| Hamilos, G | 1 |
| Zomas, A | 1 |
| Gika, D | 1 |
| Efstathiou, E | 1 |
| Grigoraki, V | 1 |
| Poziopoulos, C | 1 |
| Xilouri, I | 1 |
| Zorzou, MP | 1 |
| Anagnostopoulos, N | 1 |
| Anagnostopoulos, A | 1 |
1 trial available for thalidomide and Mononeuropathies
| Article | Year |
|---|---|
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents | 2004 |